File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective randomized control study of oral nystatin prophylaxis for candida peritonitis complicating continuous ambulatory peritoneal dialysis

TitleA prospective randomized control study of oral nystatin prophylaxis for candida peritonitis complicating continuous ambulatory peritoneal dialysis
Authors
Issue Date1996
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/ajkd
Citation
American Journal Of Kidney Diseases, 1996, v. 28 n. 4, p. 549-552 How to Cite?
AbstractA prospective randomized study of the prevention of candida peritonitis (CP) in continuous ambulatory peritoneal dialysis patients using oral nystatin given concomitantly with antibiotic therapy was carried out for 2 years. Patients were randomized into twp groups. Nystatin tablets 500,000 units four times a day were given to group 1 but not group 2 patients whenever antibiotics were prescribed. There were 199 patients at risk (mean follow-up, 18.0 months) in group 1 and 198 patients at risk (mean follow-up, 16.6 months) in group 2. The peritonitis and antibiotic prescription rates were comparable between the two groups. There were four episodes of CP in four patients in group 1 and 12 episodes in 11 patients in group 2. The probability of CP-free survival at 2 years was higher in group 1 compared with group 2 (0.974 v 0.915; P < 0.05). However, only three (75%) CP episodes in group 1 and six (50%) in group 2 were considered 'antibiotics related.' The incidence of antibiotics-related CP was 1.39 and 3.19 per 100 peritonitis episodes and 0.66 and 1.43 per 100 antibiotic prescriptions in groups 1 and 2, respectively (P = NS). We conclude that oral nystatin prophylaxis with each antibiotic prescription reduced the rate of CP in patients on continuous ambulatory peritoneal dialysis irrespective of its apparent temporal relationship to antibiotic prescription.
Persistent Identifierhttp://hdl.handle.net/10722/162131
ISSN
2015 Impact Factor: 6.269
2015 SCImago Journal Rankings: 2.313
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLo, WKen_US
dc.contributor.authorChan, CYen_US
dc.contributor.authorCheng, SWen_US
dc.contributor.authorPoon, JFMen_US
dc.contributor.authorChan, DTMen_US
dc.contributor.authorCheng, IKPen_US
dc.date.accessioned2012-09-05T05:17:31Z-
dc.date.available2012-09-05T05:17:31Z-
dc.date.issued1996en_US
dc.identifier.citationAmerican Journal Of Kidney Diseases, 1996, v. 28 n. 4, p. 549-552en_US
dc.identifier.issn0272-6386en_US
dc.identifier.urihttp://hdl.handle.net/10722/162131-
dc.description.abstractA prospective randomized study of the prevention of candida peritonitis (CP) in continuous ambulatory peritoneal dialysis patients using oral nystatin given concomitantly with antibiotic therapy was carried out for 2 years. Patients were randomized into twp groups. Nystatin tablets 500,000 units four times a day were given to group 1 but not group 2 patients whenever antibiotics were prescribed. There were 199 patients at risk (mean follow-up, 18.0 months) in group 1 and 198 patients at risk (mean follow-up, 16.6 months) in group 2. The peritonitis and antibiotic prescription rates were comparable between the two groups. There were four episodes of CP in four patients in group 1 and 12 episodes in 11 patients in group 2. The probability of CP-free survival at 2 years was higher in group 1 compared with group 2 (0.974 v 0.915; P < 0.05). However, only three (75%) CP episodes in group 1 and six (50%) in group 2 were considered 'antibiotics related.' The incidence of antibiotics-related CP was 1.39 and 3.19 per 100 peritonitis episodes and 0.66 and 1.43 per 100 antibiotic prescriptions in groups 1 and 2, respectively (P = NS). We conclude that oral nystatin prophylaxis with each antibiotic prescription reduced the rate of CP in patients on continuous ambulatory peritoneal dialysis irrespective of its apparent temporal relationship to antibiotic prescription.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/ajkden_US
dc.relation.ispartofAmerican Journal of Kidney Diseasesen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAntifungal Agents - Administration & Dosageen_US
dc.subject.meshCandidiasis - Etiology - Prevention & Controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNystatin - Administration & Dosageen_US
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatory - Adverse Effectsen_US
dc.subject.meshPeritonitis - Etiology - Prevention & Controlen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRisk Factorsen_US
dc.titleA prospective randomized control study of oral nystatin prophylaxis for candida peritonitis complicating continuous ambulatory peritoneal dialysisen_US
dc.typeArticleen_US
dc.identifier.emailChan, DTM:dtmchan@hku.hken_US
dc.identifier.authorityChan, DTM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0272-6386(96)90466-7-
dc.identifier.pmid8840945-
dc.identifier.scopuseid_2-s2.0-0029846950en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029846950&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume28en_US
dc.identifier.issue4en_US
dc.identifier.spage549en_US
dc.identifier.epage552en_US
dc.identifier.isiWOS:A1996VL78600011-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLo, WK=7201502414en_US
dc.identifier.scopusauthoridChan, CY=24517697500en_US
dc.identifier.scopusauthoridCheng, SW=7404684783en_US
dc.identifier.scopusauthoridPoon, JFM=55239321100en_US
dc.identifier.scopusauthoridChan, DTM=7402687700en_US
dc.identifier.scopusauthoridCheng, IKP=7102537483en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats